Articles Posted in Johnson & Johnson

Johnson & Johnson tort lawsuits around the country.

Published on:

Bloomberg ran an interesting article yesterday that raises the issue of whether there should be a vaginal mesh recall. There is a lot of data coming out now that supports the idea of a recall. At some point, these pharmaceutical companies need to cut their losses and not only stop making these vaginal mesh products but also recall the ones that are already on the market.

New information continues to underscore what is becoming increasingly obvious: these surgical implants are unsafe. The FDA is starting to get wind of this fact, and last month expressed more concerns about the risks of transvaginal surgical mesh used to treat pelvic organ prolapse.

This article also talks about the issue moving forward: how these defective mesh implants came on the market in the first place. As it should, it takes a long time to get approval to put new drugs and medical devices on the market. But the FDA has a loophole called the 510(k). This process is a backdoor through the approval process companies usually have to go through to get a medical device on the market. It allowed vaginal mesh manufacturers a free pass on proving their product was safe and effective since it is “substantially equivalent” to others already for sale. One problem with this loophole: the definition of “substantially equivalent” is ever-expanding. The FDA is finally catching on to this. Later this week, the FDA will gather more opinions from doctors and researchers as to whether we need to rewrite 510(k) to make it harder to get untested products on the market.

Continue Reading

Published on:

USA Today writes an article that I thought would have the false premise of “Does the Tylenol recall pose a risk for consumers?” There is no evidence this latest and greatest Tylenol recall puts consumers in harm’s way. But then it asks the larger question: are Johnson & Johnson’s products safe? Here’s the argument:

“Clearly if a company has one recall, I could say ‘Well, that’s sort of an accident, just something that was very unfortunate.’ But I think Johnson & Johnson has had it happen over and over and over again. They don’t have their act together,” says Curt Furberg, a professor of public health sciences at Wake Forest Baptist Medical Center in Winston-Salem, N.C. “I would be worried and try to go with other drugs, other pain relievers.” Furberg has served on the Food and Drug Administration’s Committee on Drug Safety and Risk Management.

That’s the key point, well-phrased. Does Johnson & Johnson have its act together and, if it doesn’t, does that make all of its products – or a least products where there appears to be the theoretical possibility that a defect could cause injury – a riskier bet for consumers?

Published on:

Alas, the good news for Johnson & Johnson on this blog ends here. A Pennsylvania jury found J&J responsible for not properly warning of Motrin’s risks and ordered Johnson & Johnson to pay $10 million to a young girl and her family.

The girl took Motrin 11 years ago as an infant and was blinded in one eye and suffered burns over 84 percent of her body.

Nobody is saying the Motrin should be recalled or even that it is anything other than a quality drug. But the jury specifically found J&J negligent in failing to provide a proper warning about Children’s Motrin’s risks. J&J did not warn that ibuprofen can trigger a severe allergic reaction. J&J’s failed defense: it was a 1 in 25 million shot.

Published on:

Johnson & Johnson. Drug Recall Lawyer Blog. It rarely ends well.
But there is some good news for J&J. Johnson & Johnson plans to introduce four promising new drugs this year to treat: (1) AIDS, (2) prostate cancer, (3) hepatitis C and (4) strokes. The sale of these drugs should be worth billions of dollars in annual revenue.

Johnson & Johnson has been a train wreck lately. They really have. Maybe I’m just nostalgic but I really think J&J can be a great company again. Here’s hoping these drugs have been well tested and can really make a difference for patients and Johnson & Johnson.

Published on:

Johnson & Johnson is back on the recall wagon again, issuing a recall for the HIV drug Prezista in Austria, Germany, Ireland, and the United Kingdom. Why the recall? Usual drill – an odd musty odor in the drugs from the shipping pallets. Maybe there would be some wisdom in buying new shipping pallets at this point.

I have taken more than my fair share of swipes on this blog at Johnson & Johnson. I’m sure my objectivity is discounted given the name of the blog: Drug Recall Lawyer Blog. Fair enough. But when the Wall Street Journal is mocking a pharmaceutical company, it is like Charlie Sheen telling you that you are out of control.

Published on:

Johnson & Johnson is purchasing medical device maker Synthes Inc. for $21.3 billion in the largest deal ever by J&J. This move will further – to say the least – J&J’s effort to capture more market share in the surgical trauma equipment and orthopedic implant markets.

A few months ago (I couldn’t find the post I did), I wrote that you should buy J&J stock because the number of recalls/screw-ups just could not continue at the frenetic pace it was maintaining. Well, I was wrong about the frenetic pace part of it but; the stock is continuing to rise which furthers my Pet Theory #853,034: product liability lawyers overestimate how much litigation matters to these huge pharma companies. J&J sets aside nearly a billion dollars for the Depuy hip replacements and we think that must be a big deal. But it is simply an accounting error to J&J in a deal of this size.

Published on:

Everybody wants in. You can’t do a search on Google without finding 20 lawyers looking for recalled DePuy hip replacement cases. It is pathetic. (Oh, now that you mention it, you can find some pandering from us here.)

Anyway, the fund that manages health benefits for several towns in New Jersey has filed a class-action lawsuit against DePuy Orthopaedics over its ASR hip implant recall. The fund accuses DePuy (Johnson & Johnson) of fraud and unjust enrichment, alleging DePuy knew its hip implants had problems and left them on the market, ostensibly hoping no one would notice (no one did for a while, actually).

In other words, their lawsuit mimics the language of virtually every DePuy hip replacement lawsuit.

Published on:

I wish Vegas had a line on things like whether Johnson & Johnson will have another recall that almost makes them caricatures of themselves. With that intro, I give you another Tylenol recall.

I’m repeating myself but Johnson & Johnson was a great company. You shouldn’t lose that status virtually overnight. (I’m using dog years to define “overnight”.) If I were a stock analyst, I would rate J&J a long-term buy because I’m convinced in the long run, someone will turn this company around. Hopefully, this is the bottom. I’ve been saying this about the housing market for a year. But, really, there has to be a bottom, right?